Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program

Inflammatory Bowel Diseases

Volumn 21, Issue 3, 2015, Pages 579-588

  Gasche, Christoph ^a   Ahmad, Tariq ^b   Tulassay, Zsolt ^c   Baumgart, Daniel C ^d   Bokemeyer, Bernd ^e   Büning, Carsten ^f   Howaldt, Stefanie ^g   Stallmach, Andreas ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d HUMBOLDT UNIVERSITY   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Hamburg Institute of Ophthalmology   (Germany)

^h JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Crohn's disease; ferric maltol; inflammatory bowel disease; iron deficiency anemia; ulcerative colitis

Indexed keywords

FERRIC MALTOL; FERRITIN; HEMOGLOBIN; PLACEBO; FERRIC ION; PYRONE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ALLERGY; ARTHRALGIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATORY BOWEL DISEASE; INTENTION TO TREAT ANALYSIS; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX PAIN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANEMIA, IRON-DEFICIENCY; CLINICAL TRIAL; COMPLICATION; MAXIMUM TOLERATED DOSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; QUALITY OF LIFE;

ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; COLITIS, ULCERATIVE; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; PYRONES; QUALITY OF LIFE;

EID: 84923507425     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000314     Document Type: Article

References (48)

1. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010; 7: 599-610.
2. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Therap. 2006; 24: 1507-1523.
3. Gasche C, Beguin Y, de Silva AD, et al. IBD and anemia. In: Gasche C, ed. Anemia in Inflammatory Bowel Diseases. Bremen: UNI-MED Verlag AG; 2008.
4. Weiss G, Goodnough LT. Anemia of chronic disease. New Engl J Med. 2005; 352: 1011-1023.
5. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007; 370: 511-520.
6. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13: 1545-1553.
7. Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004; 53: 1190-1197.
8. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2001; 7: 250-255.
9. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006; 12: 123-130.
10. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol. 1988; 10: 306-310.
11. Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol. 2009; 25: 122-128.
12. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010; 4: 63-101.
13. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013; 7: 1-33.
14. Lund EK, Wharf SG, Fairweather-Tait SJ, et al. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr. 1999; 69: 250-255.
15. Lugg S, Beal F, Nightingale P, et al. Iron treatment and inflammatory bowel disease: what happens in real practice. J Crohns Colitis. 2014; 8: 876-880.
16. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-A randomized, controlled, openlabel, multicenter study. Am J Gastroenterol. 2005; 100: 2503-2509.
17. de Silva AD, Tsironi E, Feakins RM, et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005; 22: 1097-1105.
18. Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003; 38: 543-548.
19. Kawai M, Sumimoto S, Kasajima Y, et al. A case of ulcerative colitis induced by oral ferrous sulfate. Acta Paediatr Jpn. 1992; 34: 476-478.
20. Carrier J, Aghdassi E, Platt I, et al. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001; 15: 1989-1999.
21. Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap. Am J Gastroenterol. 2011; 106: 1872-1879.
22. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009; 15: 1485-1491.
23. Erichsen K, Ulvik RJ, Grimstad T, et al. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 22: 831-838.
24. Millar AD, Rampton DS, Blake DR. Effects of iron and iron chelation in vitro on mucosal oxidant activity in ulcerative colitis. Aliment Pharmacol Ther. 2000; 14: 1163-1168.
25. WGO. World Gastroenterology Organisation global guideline. Inflammatory bowel disease: a global perspective. 2009. Available at: http: //www. guideline.gov/content.aspx?id¼15231&earch¼iron+deficiency+anemia. Accessed May 2, 2014.
26. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141: 846.e1-2-853.e1-2.
27. EMA (European Medicines Agency). New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 2013. Available at: http: //www.ema.europa.eu/docs/en-GB/document-library/ Referrals-document/IV-iron-31/WC500151308.pdf. Accessed May 1, 2014.
28. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med. 2007; 357: 93-94.
29. Gomollon F, Chowers Y, Danese S, et al. Letter: European Medicines Agency recommendations for allergic reactions to intravenous ironcontaining medicines. Aliment Pharmacol Ther. 2014; 39: 743-744.
30. WHO. Toxicological evaluation of certain food additives-International Programme on Chemical Safety IPCS. FAO Nutrition Meetings Report Series. 1980; 16: 123-129.
31. Levey JA, Barrand MA, Callingham BA, et al. Characteristics of iron (III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol. Biochem Pharmacol. 1988; 37: 2051-2057.
32. Barrand MA, Callingham BA, Dobbin P, et al. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol. 1991; 102: 723-729.
33. Barrand MA, Callingham BA. Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat. Br J Pharmacol. 1991; 102: 408-414.
34. Kelsey SM, Blake DR, Hider RC, et al. Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects. Clin Lab Haematol. 1989; 11: 287-288.
35. Kelsey SM, Hider RC, Bloor JR, et al. Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test. J Clin Pharm Ther. 1991; 16: 117-122.
36. Barrand MA, Callingham BA, Hider RC. Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine. J Pharm Pharmacol. 1987; 39: 203-211.
37. Schneider W. The fate of iron compounds in the gastrointestinal tract. Coordination-chemical facts. Arzneimittelforschung. 1987; 37: 92-95.
38. Singh RK, Barrand MA. Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate. J Pharm Pharmacol. 1990; 42: 276-279.
39. Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther. 1998; 12: 845-848.
40. WHO. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information system (WHO/NMH/NHD/MNM/111). Geneva, Switzerland: World Health Organization; 2011: 1-4.
41. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998; 43: 29-32.
42. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
43. Hauser W, Dietz N, Grandt D, et al. Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. Z Gastroenterol. 2004; 42: 131-139.
44. de Boer AG, Wijker W, Bartelsman JF, et al. Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation. Eur J Gastroenterol Hepatol. 1995; 7: 1043-1050.
45. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
46. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20: 109-117.
47. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103: 1182-1192.
48. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009; 44: 838-845.